Physician profile
Mark D Koone
NPI 1720055833
$8,342.11
in general payments reported to CMS, 2019-2025
29 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $232 · 2021: $897 · 2022: $2,316 · 2023: $1,401 · 2024: $1,576 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,982 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,981.54 |
| Education | $329.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,894.75 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,276.86 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Janssen Biotech, INC. | $870.57 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $845.20 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $433.26 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $366.62 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $298.60 | 2023-2024 | Vtama |
| Incyte Corporation | $285.83 | 2021-2025 | Opzelura |
| Genzyme Corporation | $275.58 | 2021-2024 | |
| Pfizer INC. | $234.79 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.99 | 2019-2021 | |
| Galderma Laboratories, L.P. | $152.82 | 2021-2025 | Nemluvio, Epsolay, Oracea |
| Leo Pharma INC. | $144.16 | 2022-2024 | Adbry |
| Genentech USA, INC. | $124.37 | 2019-2023 | Erivedge |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $123.36 | 2022-2025 | Klisyri, Seysara |
| Nabriva Therapeutics, Plc | $98.65 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $94.23 | 2022-2023 | Sotyktu |
| Ucb, INC. | $92.90 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $90.81 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.59 | 2022-2023 | Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $47.74 | 2021-2025 | Valchlor |
| Mayne Pharma Commercial LLC | $45.26 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $39.14 | 2023-2024 | Idacio |
| Kerecis Limited | $31.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Springworks Therapeutics, INC. | $20.56 | 2025 | Gomekli |
| Convatec INC. | $19.74 | 2024 | |
| Journey Medical Corporation | $13.55 | 2022 | |
| Kyowa Kirin, INC. | $13.13 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Koone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.